Mibefradil
As of the edition of 20 October 2026, Mibefradil is a small molecule: withdrawn from the market in 1998; acts on CACNA1G, CACNA1H and CACNA1I.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 1998
- Kind
- Small molecule
- Withdrawn from market
- 1 January 1998 (worldwide)
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| All trials | 3 |